Antimicrobial Peptides: The Quiet Revolution in Infection Control
As antimicrobial resistance (AMR) continues to climb — the WHO now calls it a top 10 global health threat — antimicrobial peptides (AMPs) are emerging as one of the most promising alternatives to conventional antibiotics.
Why AMPs Matter Now
Unlike traditional small-molecule antibiotics that target specific enzymes or pathways, AMPs disrupt bacterial membranes through physical mechanisms — making resistance development dramatically slower. After decades of academic research, several AMPs have now reached late-stage clinical trials, and the first wave of commercial products is reaching the market.
Clinical Pipeline Highlights
Several candidates are worth watching. Iseganan (IB-367) is in Phase 3 for oral mucositis. Pexiganan (MSI-78) targets diabetic foot infections. PL-5 (a synthetic alpha-helical AMP) is in Phase 3 for skin and soft tissue infections. On the agricultural side, Nisin-based formulations have been used as food preservatives for years, and plant-expressed AMPs are entering field trials for crop protection.
Delivery and Stability Challenges
The historical barriers to AMP development — protease susceptibility, systemic toxicity, and manufacturing cost — are being systematically addressed. PEGylation, lipidation, cyclization, and D-amino acid substitution improve half-life. Lipid nanoparticle and polymer-based delivery systems protect peptides in circulation. And advances in recombinant expression (yeast, E. coli, plant-based) are bringing production costs down from thousands to hundreds of dollars per gram.
The Investment Landscape
Venture funding for AMP-focused biotechs has risen steadily, with over $2 billion invested since 2020. Key players include Polyphor (now Spexis), Adenium Biotech, and academic spinouts from MIT, UCSF, and the University of Queensland. The market for peptide antibiotics alone is projected at $5–8 billion by 2032.